Vilde D Haakensen

Another failure for TIGIT as a target as Skyscraper-03 failed to improve survival for pts undergoing CRT for NSCLC when adding anti-TIGIT to PD-L1-inh.

So far, neoadjuvant chemo-IO is given to pts with respectable disease. But could it also be used for downstaging of borderline respectable disease? That is explored in the MDT-bridge trial. Borderline respectable pts where given 2 cycles before new MDT. 71% got surgery.

Tarlatamab continues to impress. In the Dellphi 303 study where Tarlatamab was given with chemo and PD-L1 inhibitor from the start in 1L. 👉12m OS 81% NB! Phase 1b non-randomised, n=96. This promises a new era for our patients!

Zongertinib and sevabertinib are both promising as HER2-TKIs also in 1L. Presented by Sanjay Popat and Xiuning Le. Awaiting results from phase 3 trials.

No survival benefit of adding atezolizumab to CRT for SCLC-LD in the ACHIlES-Trial presented by Bjørn Henning Grønberg at #ASCO25 today. The discussant stressed the exceptionally good outcome in the control arm, the benefit of PCI and the possibly of twice-daily fractionation.

CM816 viser nå signifikant overlevelse abb neoadjuvant kjemo-nivo sammenlignet med kjemo. Presentert av Patrick Frode på #ASCO25

Prognostic value of FDG-PET before treatment with ipi/nivo +/- the UV1 vaccine for pts with mesothelioma. Congrats Solfrid Thunold! link.springer.com/article/10.100…

@fkbmatrix @KjetilTasken @Oslounivsykehus @HellandAslaug @HRussnes @livefagereng Congratulations to both @KjetilTasken and Andras Kleppe!

Warm congratulations to @KjetilTasken on receiving the Excellent Researcher Award at @Oslounivsykehus 👏👏matrix-fkb.no/no/aktuelt/kje…

Åslaug Helland oppdaterer om IMPRESS-Norway på ASCO #ASCO24 dagensmedisin.no/asco-asco-2024…

OUS får nøkkelrolle i stort europeisk kreftsamarbeid. oslo-universitetssykehus.no/om-oss/nyheter… @KaasaStein

Survival-data from the NIPU-trial randomising pts with pleural mesotheliom to double ICI alone or with telomerase vaccine UV1. sciencedirect.com/science/articl…

Veldig gøy med positive resultater for NIPU-studien! Dataene presenteres på ESMO. @HellandAslaug @Ultimovacs

Ultimovacs kunngjorde tirsdag kveld at det har vært en signifikant og klinisk relevant økning i totaloverlevelse blant pasienter med brysthinnekreft som mottok kreftvaksinen UV1 i fase 2-studien NIPU. healthtalk.no/pasienter-med-…

Nesten alene verdt Aftenposten-abonnementet. Ære være norsk presse!

Åslaug Helland fikk i dag overrakt Kong Olav´s kreftforskningspris av Kong Harald i Universitetets Aula. Gratulerer, Åslaug - vel fortjent! @HellandAslaug

Today, @HellandAslaug received the prestigious King Olav V's Cancer Research Prize from King Harald V of Norway. A well-deserved recognition, congratulations!

Alkohol har en negativ effekt på hele 200 sykdommer. Gitt det er det en naturlig konsekvens at kostrådene, som er der for å ivareta hensyn til helsen, anbefaler avhold. vg.no/nyheter/innenr…

@HellandAslaug @DNVA1 @fkbmatrix Gratulerer!!

I am deeply honoured to be nominated and elected as member of The Norwegian Academy of Science and Letters (Vitenskapsakademiet). Looking forward to participate! @DNVA1 @fkbmatrix

@BHGronberg Great study with important information to all clinicians!! Do you have a screening-log indicating if the inclusion rate in your trial was different for older than younger patients?

AddThis | Home doi.org/10.1016/j.jtho… Kristin's third article for her PhD is just published in JTO. Results from our subgroup analysis suggest that older LS SCLC patients should receive same treatment as younger patients.

Great scientific input and lots of inspiration from excellent researchers: @MariamJHanjani @DouglasHanahan @Aslan_Tasdogan #CancerCrosslinks @OsloCancer